Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved SurvivalAntonio Palumbo, Michèle Cavo, Sara Bringhen et al.|Journal of Clinical Oncology|2014Cited by 210
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survivalSimone Ferrero, Antonio Palumbo, Marco Ladetto et al.|Leukemia|2014Cited by 83
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myelomaAlessandra Larocca, Antonio Palumbo, Sara Bringhen et al.|Leukemia|2016Cited by 46
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)Massimo Breccia, Filíppo Gherlinzoni, Monica Crugnola et al.|Cancer|2025Cited by 10
LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVALMarco Ladetto, Antonio Palumbo, Simone Ferrero et al.|Blood|2011Cited by 9